Dyne is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. 

Biotechnology

Dyne Therapeutics

Debra is an accomplished R&D leader with more than 20 years of regulatory experience in biotech and the life sciences. She has reviewed and authored numerous successful INDs, CTAs, NDAs, MAAs and submissions for breakthrough, fast track, orphan drug and pediatric designations to advance innovative and data-driven science. Prior to joining Dyne, Debra led the regulatory organization at Sage Therapeutics, overseeing regulatory initiatives across a pipeline of products to address neurological and psychiatric disorders. During her time at Sage, she led the company through the approval of ZULRESSO® (brexanolone), the first and only treatment specifically indicated for postpartum depression. Prior to Sage, Ms. Feldman held various regulatory roles focused on multiple therapeutic areas, including rare diseases. Debra holds a B.A. from University of Massachusetts, Amherst, a degree in nutritional science from Simmons College and an M.P.H. from Boston University.

Debra Feldman

Rick brings significant life science and public company finance experience to his role at Dyne. Previously, he served as corporate controller at Kaleido Biosciences, where he played a key role in the execution of the company’s Initial Public Offering and led the accounting group’s transition from a private to a public company. Prior to joining Kaleido, he served as corporate controller at X4 Pharmaceuticals and Ocata Therapeutics. At Ocata, Rick was a significant contributor to the company’s acquisition by Astellas Pharma and the subsequent integration between the companies. He began his career in public accounting in the Health Industries practice at PricewaterhouseCoopers. Rick is a certified public accountant in the Commonwealth of Massachusetts and received his B.S. in accounting from Boston College and his M.B.A. from the University of Massachusetts, Amherst.

Rick Scalzo

Josh brings extensive healthcare leadership experience to his role at Dyne. Previously, he served as a chief operating officer and chief financial officer of Kaleido Biosciences, where he led the company’s financings including its initial public offering, and helped bring the lead program into Phase 2 development. Prior to joining Kaleido, Josh was COO and CFO at Versartis, where he spearheaded the company’s financial strategy including the successful completion of its IPO, played an integral role in product strategy, and helped negotiate the company’s first product partnership. His previous roles include serving as executive vice president of finance and principal financial officer at Pharmacyclics; CFO at ZELTIQ Aesthetics, where he led the company through its initial public offering, led the international product launch for CoolSculpting and also served in corporate development; and director of finance at Proteolix, Inc., assisting in the sale of the company to Onyx Pharmaceuticals. He also held investment banking positions at Citigroup Global Markets, Inc. and Morgan Stanley. Over the course of his career, Josh has raised nearly $2 billion in the capital. Josh serves as Chairman of the Board of Amphista Therapeutics, a company focused on advancing targeted protein degradation therapeutics. He holds a B.A. in business administration from the University of Notre Dame.

Joshua Brumm

Amy brings 20 years of experience in corporate communications in the life science industry to her role at Dyne, including managing investor relations, building employee communications programs, expanding corporate philanthropic initiatives, and executing product launch communications. Prior to joining Dyne, Amy was Vice President, Communications and Investor Relations at Kaleido Biosciences, during which time she helped lead the company’s Initial Public Offering, implemented digital and social media activities as well as oversaw internal and executive communications. Amy previously managed corporate communications at ImmunoGen, led philanthropy and employee communications at Cubist Pharmaceuticals, and held various roles at Biogen, including managing product communications for its multiple sclerosis franchise and media relations, as well as overseeing the company’s Foundation. Amy received her A.B. in English and American Literature from Bowdoin College.

Amy Reilly

Wildon brings expertise in clinical development and medical affairs in neuromuscular diseases and oligonucleotide therapies. He joined Dyne from Biogen, Inc., where he was vice president, and global head of neuromuscular diseases, and medical affairs. During his 10 years at Biogen, Wildon led the development and life cycle management of SPINRAZA® (nusinersen), an oligonucleotide and the first therapy approved for the treatment of spinal muscular atrophy. He also led the late-stage development of tofersen, an investigational oligonucleotide therapy for amyotrophic lateral sclerosis, oversaw clinical and biomarker development for Biogen’s neuromuscular disease portfolio and began his tenure at the company leading pharmacovigilance for multiple product candidates. Previously, Wildon was an Assistant Professor in Medicine at Harvard Medical School and a physician at Brigham and Women’s Hospital and the VA Boston Healthcare System. He received his M.D. from the University of Missouri School of Medicine and an MPH in clinical effectiveness from Harvard University School of Public Health.

Wildon Farwell

Dr. Dugar brings to Dyne over 20 years of broad experience across medical affairs, clinical and commercial development, and real-world evidence (RWE) generation. Prior to joining Dyne, Dr. Dugar served as vice president and global head of medical affairs at Sarepta Therapeutics, Inc., where he built the company’s medical affairs organization. Previously, he led all commercial and market access efforts for Intra-Cellular Therapies, Inc. as vice president and head of commercial development. Dr. Dugar joined Intra-Cellular Therapies following his tenure at Roche, where he was global head of clinical development science and innovation and global head of the external development group, including work in oligonucleotides. Previously, he spent 13 years at Pfizer Inc. in various roles, most recently serving as vice president, global head of clinical development, and medical affairs of the biosimilars business unit. Dr. Dugar began his career at the National Institutes of Health. He completed a pharmacoeconomics and outcomes research fellowship at the University of Michigan School of Public Health. Dr. Dugar earned an MBA from The Pennsylvania State University and a Ph.D. in pharmacology from The Pennsylvania State University College of Medicine.

Ashish Dugar

Kate brings over 15 years of experience in business and human resources to her role at Dyne. She has experience developing a global talent acquisition strategy, designing and executing people and leadership development programs, and launching employee engagement initiatives. Prior to joining Dyne, Kate was an HR business partner and chief of staff at Ipsen. She built her career both in-house and as a consultant in the biopharmaceutical industry including at Ipsen, Biogen, and Deloitte. She has experience both managing small teams and leading large company projects and programs. Kate received her B.S. from the University of Connecticut and her MSA from Boston College.

Kate Mitchell

Joanne Bryce is the current Director of Finance at [Dyne Therapeutics](/org/dyne-therapeutics). Joanne has previous experience working as the CFO for WiTricity Corporation and as VP Finance/Interim CFO for Jingle Networks, Inc. Bryce has also been an independent consultant for various companies and their previous positions also include Director of Finance for Narrative Communications and Controller for Aimtech Corporation.

Joanne Bryce completed a Bachelor of Science in Accounting from [Babson College](/org/babson-college) and went on to earn their Certified Public Accountant certification from the Board of Public Accountancy.

Their manager is Joshua Brumm, President and Chief Executive Officer. Some of their coworkers include Susanna High - Chief Operating Officer, Amy Reilly - VP, Corporate Communications and Investor Relations, and Rick Scalzo - VP, Accounting and Administration.

Joanne Bryce

Dirk Kersten is the Director at [Dyne Therapeutics](/org/dyne-therapeutics). Dirk has over 18 years of experience in venture capital and growth equity investments in emerging healthcare and technology companies. Prior to joining [Dyne Therapeutics](/org/dyne-therapeutics), Dirk was a Managing Director at [INKEF Capital](/org/inkef-capital), where they made venture capital and growth equity investments in healthcare and technology companies. Before that, Dirk was the Partner & President US office at [Gilde Healthcare](/org/gilde-healthcare), where they made venture capital and growth equity investments in healthcare companies. Dirk has also worked as an Associate at Venture Creation Management, a corporate finance boutique, and as a Consultant at Fource Consulting, a strategy consulting firm for the telecom and new media industry. Dirk has a proven track record of successful investments in healthcare and technology companies and is an expert in the field.

Dirk Kersten has a MSc in Physics from the [University of Groningen](/org/university-of-groningen).

Dirk Kersten

Francesco brings more than two decades of experience in development, including a focus on rare neuromuscular diseases as well as Duchenne muscular dystrophy (DMD). He joins Dyne from Ultragenyx Pharmaceutical Inc., where he served as vice president of global clinical development and oversaw all stages of the development of neuromuscular and neurology product candidates, providing strategic direction and technical leadership to the clinical development team, including for the company’s gene therapy program in DMD. While at Ultragenyx, he was also a member of the DMD Gene Therapy Working Group, comprised of leading experts from the industry and academia collaborating to optimize and provide guidelines for gene therapy in DMD. Previously, Dr. Bibbiani was the vice president of clinical development for PTC Therapeutics, Inc., overseeing multiple clinical trials in DMD and lifecycle management for all products in its neuromuscular portfolio. Prior to PTC Therapeutics, he held several roles at Eisai, Inc. as a project and clinical lead, overseeing global clinical development plans and leading multiple New Drug Applications. He received his M.D. and board certification in neurology from the University of Pisa, Italy. Following that, he completed his fellowship at the National Institutes of Health in Experimental Therapeutics.

Francesco Bibbiani

Gene Kim

John brings nearly 20 years of experience in a global biopharmaceutical setting with expertise managing both exploratory and GLP nonclinical toxicology studies. John’s breadth of portfolio support includes antisense oligonucleotide, small molecule and biologic programs, across many therapeutic areas and all stages of development. Prior to joining Dyne, John was vice president of preclinical development at Wave Life Sciences where he established toxicology as a core discipline and led cross-functional teams aimed at developing and implementing early safety screening strategies. Prior to Wave, John held positions of increasing responsibility at first Schering-Plough and then Pfizer. While at Pfizer, John was a recognized leader in developing mechanism-based human risk assessment projects and led highly effective cross-discipline teams driving novel approaches to toxicology studies. John received his Ph.D. in molecular toxicology from Purdue University and his B.S. from the University of Wisconsin-Madison.

John Davis

Bruce Wentworth is the Senior Scientific Advisor at [Dyne Therapeutics](/org/dyne-therapeutics). Bruce has over 25 years of experience in the biotech industry, including holding positions such as VP, Head of Research, Sr. Director, and Principal Owner. 

Bruce started their career as a Scientist at BioSurface Technology in 1991. In 1994, they moved to Genzyme where they worked their way up to Head of Research. In 2004, they left Genzyme to join Medtronic-Genzyme BioTherapeutics as their Head of Research. Bruce remained there until 2008 when they left to start their own company, BMW Research Consulting. 

In 2015, they joined [Sarepta Therapeutics](/org/sarepta-therapeutics) as their VP, Head of Research. Bruce was responsible for advancing the development and clinical data of ExonDys 51, an exon skipping drug, through to FDA approval. Bruce also led a diverse R&D group comprised of 10 PhDs and 20 Research Associates in Cambridge MA and Corvallis OR. 

Bruce has been instrumental in designing systems to develop next generation PMO drugs through IND enabling studies and supportive bioanaytical assays. Bruce has also championed faster and cheaper development of novel cell penetrating peptides for improved uptake of drug candidates. In addition, they have established collaboration exploring next generation methods for the rapid synthesis of PMO drugs. Lastly, they designed and implemented Stage Gate portfolio based structure for the conduct of biotech R&D.

Bruce Wentworth received their PhD in molecular genetics from UMass Chan Medical School and their Bachelor of Arts in biology from [Boston University](/org/boston-university).

Bruce Wentworth reports to Romesh Subramanian, Chief Scientific Officer.

Bruce Wentworth

Molly brings extensive experience in patient advocacy and community engagement to her role at Dyne. She previously served as chief executive officer of the Myotonic Dystrophy Foundation, an organization dedicated to advancing research and enhancing the quality of life of people living with myotonic dystrophy. In that role, she led the strategic direction and administrative oversight for the comprehensive programmatic and fundraising efforts of the foundation and its staff. Molly has over 25 years of leadership-level experience building, implementing, and running award-winning domestic and international community programs for organizations in both the private and nonprofit sectors. She has created partnerships with a range of governmental, nonprofit, and private sector stakeholders to launch initiatives targeting key national issues such as childhood obesity prevention and components of healthcare reform. She received her M.A. from the University of Iowa.

Molly White

John brings a wealth of CMC biopharmaceutical development and cGMP manufacturing experience across multiple biologic expression systems and small molecules. John previously held roles of increasing responsibility at Proteon Therapeutics, including most recently as vice president of manufacturing and process development, and also served as associate director of manufacturing at Dyax Corporation. He received his B.S. in biochemistry from Merrimack College and his M.B.A from Bentley University.

John Najim

Oxana is an accomplished R&D leader with a strong track record of discovering and developing first-in-class therapeutics for rare genetic diseases. Prior to joining Dyne, Oxana served as head of musculoskeletal and renal research in Sanofi’s rare disease and neurological unit, advancing a pipeline of drug candidates using multiple therapeutic modalities, including nucleic acids, proteins, and small molecules. Previously, she served in various capacities of increasing responsibility at Genzyme, managing research in genetics, disease mechanisms, target discovery/validation, and translational biomarkers in rare renal, metabolic, skeletal, and neuromuscular diseases. She has authored numerous patents, invited reviews, editorials, book chapters, and original research articles in major scientific journals, including Nature, Nature Medicine, Cell, and Molecular Cell. Oxana received her Ph.D. in genetics from Moscow Genetics Institute, followed by postdoctoral fellowship training in neuromuscular diseases at the Howard Hughes Medical Institute at the University of Iowa.

Oxana Beskrovnaya

Carlo has more than three decades of experience in the biopharmaceutical industry, including in rare disease drug development. Carlo is currently an operating partner at Forbion, a life sciences venture capital firm. Previously, he held several positions of increasing responsibility during his more than 25 years at Sanofi Genzyme, including senior vice president, chief medical officer, and head of global medical affairs. He also served as senior vice president of global market access and held various roles at Genzyme’s European headquarters. He is chairman of the Board at Inversago Pharma, EryDel SpA, Azafaros B.V., VectorY Therapeutics, and a member of the Board of Numab Therapeutics AG. Carlo is also a founding member of the International Rare Diseases Research Consortium.

He received his medical degree from the University of Modena and Reggio Emilia, Italy.

Carlo Incerti

Chris brings extensive clinical development experience to Dyne, including leadership of early to late-stage clinical trials across multiple disease areas. Prior to joining Dyne, Chris served as vice president of rare genetic disease clinical development at Agios Pharmaceuticals, where he oversaw development across several hemolytic anemia indications. In his previous role as vice president of clinical development at Sarepta Therapeutics, he focused on advancing candidate therapies for rare neuromuscular diseases. Chris received his B.A. in chemistry from Haverford College and his M.D. from the University of Massachusetts Medical School. He completed his residency in internal medicine at Tufts Medical Center, a fellowship in nephrology at the Beth Israel Deaconess Medical Center in Boston, and an M.S. in clinical care research at the Tufts School of Biomedical Sciences.

Chris Mix

Dr. Klein is currently chief business officer at [CRISPR Therapeutics](/org/crispr-therapeutics), where he previously served as vice president of strategy and corporate development. Before joining CRISPR, he was an associate partner at [McKinsey & Company](/org/mckinsey-company), where he was a leader in the biotech practice and served a number of biotech companies on a wide range of topics, from strategy to operations. He received his B.S. in biochemistry and physics from the University of Wisconsin-Madison and his Ph.D. in biophysics from [Stanford University](/org/stanford).

Lawrence Klein

Jonathan brings life science business development and corporate strategy experience to Dyne. Most recently, Jonathan held a business development role at Editas Medicine, where he completed a variety of significant transactions, led strategic planning activities, and collaborated on the company’s initial public offering. Prior to Editas, Jonathan was a consultant at the Boston Consulting Group, focusing on the pharmaceutical and biotechnology sectors. He was previously a healthcare services researcher at The University of North Carolina at Chapel Hill. Jonathan earned his M.D. from the Perelman School of Medicine at the University of Pennsylvania and his B.A. in public policy and economics from UNC Chapel Hill, where he was a Morehead-Cain Scholar.

Jonathan McNeill

Lubner serves as executive vice president and chief financial officer of Ra Pharma, acquired by UCB in April 2020. Before joining Ra Pharma, he served as a member of the senior management team of Tetraphase Pharmaceuticals, Inc. and PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company, and at ProScript, where Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer multiple myeloma, was discovered. In addition to Dyne’s Board of Directors, he previously served on the Board of Directors of Nightstar Therapeutics plc (Nasdaq: NITE), a company focused on the development of one-time retinal gene therapies for patients suffering from rare inherited retinal diseases, which was acquired by [Biogen](/org/biogen) in June 2019. Lubner is a Certified Public Accountant. He received his B.S. in business administration from [Northeastern University](/org/northeastern-university) and an M.S. in taxation from [Bentley University](/org/bentley-university).

David Lubner

Susanna has more than two decades of experience leading corporate strategy, portfolio management, business planning and operations for biotechnology companies. In her most recent position, she served as chief operating officer of bluebird bio where her numerous responsibilities included the advancement of the company’s severe genetic disease portfolio, leading to the European filing and then approval of ZYNTEGLO®, a gene therapy for the treatment of transfusion-dependent beta-thalassemia, as well as overseeing the build-out of its European organization. Before joining bluebird, Susanna worked in roles of increasing responsibility at Alnylam Pharmaceuticals, including as senior vice president, strategy and business integration, where she led corporate and portfolio strategy, program and alliance management, business planning and information technology. Previously, she supported corporate strategy and business operations at Millennium Pharmaceuticals (now Takeda Oncology). Susanna holds an M.S. in economics and business management from Bocconi University in Italy and an M.B.A. from the MIT Sloan School of Management.

Susanna High

Dan is an accomplished intellectual property attorney with an extensive knowledge of the pharmaceutical and biotech industries. Prior to joining Dyne, Dan served as senior corporate counsel at Celgene. In that role, he led the intellectual property group for the Massachusetts office while working on a variety of global business deals, collaborations and product development teams. While at Celgene, Dan was patent counsel for project teams that launched two new medicines. Previously, Dan was intellectual property counsel at Sunovion Pharmaceuticals. He began his legal career working at the law firms of Goodwin Procter and Testa, Hurwitz & Thibeault, where he worked with a variety of life science companies. Dan received his B.A. in biology from Swarthmore College, his M.S. in pharmacology from University of Pennsylvania and his J.D. from Boston University School of Law.

Dyne Therapeutics

Org chart

Teams

Leadership Team

CEO and Executive Team

Board of Directors

Discover similar companies